Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180256 | 0.93 | — | — | |
| SCHEMBL445540 | 0.93 | — | — | |
| SCHEMBL2829694 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL29056655 | 0.91 | CYP1A2 (0.52) | CYP1A2ADRA2AALDH1A1HTR6 | |
| Hydrochloric Acid SCHEMBL6778419 | 0.91 | CYP1A2 (0.52) | CYP1A2ADRA2AALDH1A1HTR6 | |
| Hydrochloric Acid SCHEMBL29056653 | 0.91 | CYP1A2 (0.52) | CYP1A2ADRA2AALDH1A1HTR6 | |
| Hydrochloric Acid SCHEMBL2673742 | 0.91 | CYP1A2 (0.52) | CYP1A2ADRA2AALDH1A1HTR6 | |
| SCHEMBL1143606 | 0.88 | CYP1A2 (0.58) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| SCHEMBL7207815 | 0.87 | CYP1A2 (0.62) | CYP1A2ADRA2AALDH1A1 | |
| SCHEMBL24446371 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677723-B | 5-HT2A receptor antagonists and their use for treating central nervous system disorders | 瀚远医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-4126839-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
| CN-115677723-A | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115397818-A | Aminopyrimidine derivatives and their use as modulators of arene receptors | 东亚ST株式会社 | 2022-11-25 | — | — | CN | disclosed |
| CN-113214289-B | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-113214289-A | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2021147818-A1 | 5-HT2A RECEPTOR ANTAGONIST AND APPLICATION THEREOF IN TREATING CENTRAL NERVOUS SYSTEM DISEASES | 瀚远医药有限公司 | 2021-07-29 | — | — | WO | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| WO-2016186967-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| EP-2118048-B1 | MALE CONTRACEPTIVE | AMOBI NNAEMEKA IKECHUKWU (GB) | 2016-11-23 | — | — | EP | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2013064884-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-1888565-B1 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL SA (ES) | 2011-03-23 | — | — | EP | disclosed |
| WO-2008122614-A1 | 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008087421-A2 | MALE CONTRACEPTIVE | KING'S COLLEGE LONDON (GB) | 2008-07-24 | — | — | WO | disclosed |
| US-5919934-A | BISAMINOTHIOL AND AMINO COMPOUNDS WITH APPENDED PHARMACOPHORES, METAL COMPLEXES OF THESE COMPOUNDS; | THE GEORGE WASHINGTON UNIVERSITY (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998037055-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CANCER IMAGING AND THERAPY | THE GEORGE WASHINGTON UNIVERSITY (US) | 1998-08-27 | — | — | WO | disclosed |
| EP-0346744-A1 | Condensed diazepinones, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | CYP1A2 162/4885ADRA2A 745/4885ALDH1A1 236/4885 |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | CYP1A2 146/4885ADRA2A 463/4885ALDH1A1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.